Skip to main content
. 2022 Nov 23;94(1):1–9. doi: 10.1136/jnnp-2022-328799

Figure 1.

Figure 1

EAIRs of TEAEs, serious TEAEs and infections among evobrutinib-treated and placebo-treated patients in MS, RA, SLE and across indications. EAIR, exposure-adjusted incidence rates; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TEAEs, treatment-emergent adverse events.